AxoGen, Inc. (LT3.F)

5,95 -0,40 (-6,30%) Börsenschluss: 03:32PM CEST

AxoGen, Inc.

13631 Progress Boulevard
Suite 400
Alachua, FL 32615
United States
386 462 6800
https://www.axogeninc.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 426

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Karen Zaderej	Chairman, President & CEO	798,76k	140,89k	1962
Mr. Michael Donovan	Vice President of Operations	380,57k	28,82k	1965
Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A.	Chief Financial Officer	N/A	N/A	1975
Mr. Harold D. Tamayo	Vice President of Finance & Investor Relations	N/A	N/A	N/A
Mr. Marc A. Began	Executive VP, General Counsel & Chief Compliance Officer	N/A	N/A	1968
Ms. Doris Quackenbush	Vice President of Sales	N/A	N/A	N/A
Mr. Jens Schroeder Kemp	Chief Marketing Officer	N/A	N/A	N/A
Mr. Erick DeVinney	Chief Innovation Officer	N/A	N/A	1976
Dr. Ivica Ducic M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Corporate Governance

AxoGen, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 2. Die grundlegenden Scores sind Audit: 1, Vorstand: 4, Shareholderrechte: 1, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.